MARKET

ITCI

ITCI

INTRA CELLULAR
NASDAQ

Real-time Quotes | Nasdaq Last Sale

37.96
+0.79
+2.13%
After Hours: 37.96 0 0.00% 16:00 09/23 EDT
OPEN
38.20
PREV CLOSE
37.17
HIGH
38.36
LOW
37.21
VOLUME
432.03K
TURNOVER
--
52 WEEK HIGH
44.80
52 WEEK LOW
22.92
MARKET CAP
3.09B
P/E (TTM)
-12.4590
1D
5D
1M
3M
1Y
5Y
Biogen, Sage are new buys as Needham initiates coverage on neuro-focused stocks
Biogen (NASDAQ:BIIB) and Sage Therapeutics (NASDAQ:SAGE) have been granted buy ratings at Needham as the firm initiated the coverage on companies focused on neurological diseases despite hurdles for therapeutic development
Seekingalpha · 9h ago
Needham Initiates Coverage On Intra-Cellular Therapies with Buy Rating, Announces Price Target of $55
Needham analyst Ami Fadia initiates coverage on Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy rating and announces Price Target of $55.
Benzinga · 13h ago
Needham Starts Intra-Cellular Therapies at Buy With $55 Price Target
MT Newswires · 14h ago
Intra-Cellular Therapies to Present at the 2021 Cantor Virtual Global Healthcare Conference
Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that Sharon Mates, Ph.D., Chief Executive Officer and Ch...
GlobeNewswire · 1d ago
Top Stocks Targeting the Underserved $5.7B Parkinson's Opportunity (PRTA, ITCI, ATRX, QURE, GMAB, IMPL, AMRX)
WallStreetPR · 1d ago
Should You Consider Investing in Intra-Cellular Therapies (ITCI)?
Wasatch Global Investors, an investment management firm, published its “Wasatch Ultra Growth Fund” second quarter 2021 investor letter – a copy of which can be downloaded here. A quarterly return of 6.02% was recorded by the fund’s investor class for the Q...
Insider Monkey · 2d ago
Looking Into Intra-Cellular Therapies's Return On Capital Employed
Intra-Cellular Therapies (NASDAQ:ITCI) brought in sales totaling $20.05 million during Q2 according to data provided by Benzinga Pro. However, earnings decreased 29.92%, resulting in a loss of $69.14 million.
Benzinga · 3d ago
Jefferies Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $70
Jefferies analyst Andrew Tsai maintains Intra-Cellular Therapies (NASDAQ:ITCI) with a Buy and raises the price target from $55 to $70.
Benzinga · 3d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ITCI. Analyze the recent business situations of INTRA CELLULAR through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 10 analysts

Strong Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ITCI stock price target is 52.11 with a high estimate of 81.00 and a low estimate of 40.00.
EPS
Institutional Holdings
Institutions: 254
Institutional Holdings: 71.64M
% Owned: 88.08%
Shares Outstanding: 81.34M
TypeInstitutionsShares
Increased
55
2.05M
New
30
851.96K
Decreased
67
3.09M
Sold Out
14
907.30K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+1.87%
Pharmaceuticals & Medical Research
+1.27%
Key Executives
Chief Financial Officer/Senior Vice President - Finance/Treasurer/Assistant Secretary
Lawrence Hineline
Executive Vice President/General Counsel/Secretary
Michael Halstead
Executive Vice President
Mark Neumann
Senior Vice President
Suresh Durgam
Lead Director/Independent Director
Robert Van Nostrand
Director/Chief Executive Officer/President/Chairman
Sharon Mates
Independent Director
Christopher Alafi
Independent Director
Richard Lerner
Independent Director
Joel Marcus
Independent Director
Michael Rawlins
Independent Director
Rory Riggs
No Data
About ITCI
Intra-Cellular Therapies, Inc. (ITI) is a biopharmaceutical company that is focused on the discovery, clinical development, and commercialization of small molecule drugs that address underserved medical needs primarily in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system (CNS). The Company offers CAPLYTA for the treatment of schizophrenia as is typical for antipsychotics. Its lumateperone bipolar depression clinical program consists of three monotherapy studies and one adjunctive study. The Company also initiated its third monotherapy Phase III study, Study 403, evaluating lumateperone as monotherapy in the treatment of major depressive episodes associated with Bipolar I or Bipolar II disorder.

Webull offers kinds of Intra-Cellular Therapies Inc stock information, including NASDAQ:ITCI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ITCI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ITCI stock methods without spending real money on the virtual paper trading platform.